**2. Current pharmaceutical market in Asia**

The following are the trends as of 2022 that the selected countries under study observe (**Table 1**) [1].

A 4% of global drug development pipelines are being witnessed by companies of Korea having 900 new medicines under development [2].

World Bank data in 2012 stated that Singapore expends 4.7% of its GDP into the healthcare industry. In Singapore on annual basis, the pharmaceutical industry subsidizes over 85% of the total biomedical sciences manufacturing yield. According to World Health Organization (WHO), the healthcare system of Singapore holds the sixth position globally [3].

Similar to various countries in Asia such as China, Korea and Japan, the population in Thailand is also facing rapid ageing. Over 20% of Thailand's population will be older than 60 by 2025. The threat of developing respiratory diseases, cancer and diabetes increases with age there will be a higher demand for newer and better pharmaceutical products in Thailand [4].
